Pfizer has voluntarily withdrawn Oxbryta (voxelotor) from all global markets due to safety concerns, citing an imbalance in vaso-occlusive crises and fatal events.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.